Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Indrova

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
International Journal of Oncology|May 14, 2011
Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancerJ Bubenik, J Zeuthen, M Indrova, et al.
International Journal of Oncology|May 10, 2011
IFN-alpha therapy of renal-cell carcinoma - defect of lymphocyte sensitivity to mitogenic and activating cytokine signals in patients not-responding to therapyM Indrova, J Bubenik, J Jakoubkova, et al.
Journal of Biological Regulators and Homeostatic Agents|January 6, 2012
Effects of 5-azacytidine and trichostatin A on dendritic cell maturationI Stepanek, M Indrova, J Bieblova, et al.
International Journal of Oncology|February 12, 1998
Immunogenicity, immunosensitivity and cell surface adhesiveness of tumour vaccines carrying an inserted CD80 geneM Indrova, J Bubenik, P Rossner, et al.
International Journal of Oncology|April 30, 2011
Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 geneJ Bubenik, P Rossner, D Bubenikova, et al.
International Journal of Oncology|May 3, 2011
Genetically modified tumour vaccinesP Rossner, J Bubenik, M Indrova, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1993
The influence of tumor immunity suppressors on the effector stage of human and animal lymphokine-activated killer cellsI F Abronina, M Indrova, J Bubenic, et al.
Neoplasma|September 8, 2007
Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I moleculesS Nemeckova, M Smahel, P Hainz, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
International Journal of Oncology|May 14, 2011
Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancerJ Bubenik, J Zeuthen, M Indrova, et al.
International Journal of Oncology|May 10, 2011
IFN-alpha therapy of renal-cell carcinoma - defect of lymphocyte sensitivity to mitogenic and activating cytokine signals in patients not-responding to therapyM Indrova, J Bubenik, J Jakoubkova, et al.
Journal of Biological Regulators and Homeostatic Agents|January 6, 2012
Effects of 5-azacytidine and trichostatin A on dendritic cell maturationI Stepanek, M Indrova, J Bieblova, et al.
International Journal of Oncology|February 12, 1998
Immunogenicity, immunosensitivity and cell surface adhesiveness of tumour vaccines carrying an inserted CD80 geneM Indrova, J Bubenik, P Rossner, et al.
International Journal of Oncology|April 30, 2011
Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 geneJ Bubenik, P Rossner, D Bubenikova, et al.
International Journal of Oncology|May 3, 2011
Genetically modified tumour vaccinesP Rossner, J Bubenik, M Indrova, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1993
The influence of tumor immunity suppressors on the effector stage of human and animal lymphokine-activated killer cellsI F Abronina, M Indrova, J Bubenic, et al.
Neoplasma|September 8, 2007
Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I moleculesS Nemeckova, M Smahel, P Hainz, et al.
Pageof 1